| HOME >> MEDICINE >> TECHNOLOGY |
205
(4)
-Restructuring charges
2,067
(5)
9,881
(5)Impairment charges
-7,080
(6)Acquired in-process research and development adjustments
100,000
(7)
-Interest expense adjustment
15,413
(8)
17,307
(8)Change in fair value of investments adjustment
(7,931)
(9)
-Other income adjustment
(8,522)
(10)
-Income tax adjustment
(58,491)
(11)
(35,787)
(11)*Noncontrolling Interest adjustments:Impairment charges
-175,000Other revenue
(244)(11)Research and development
267,140Selling, general and administrative5311,411Interest income
(21)(5)Interest expense
-97Restructuring charges
1,014-Income taxes
(1,004)(12,647)Impairment charge tax benefit
-(74,235)Less amount attributable to noncontrolling interest
(302)(96,750)83,48733,931ADJUSTED NET INCOME ATTRIBUTABLE TO CEPHALON, INC.
$ 177,103$ 130,489BASIC ADJUSTED INCOME PER COMMON SHARE
$
2.35$
.75DILUTED ADJUSTED INCOME PER COMMON SHARE
$
2.19$
.66WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING
75,35574,720WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-ASSUMING DILUTION
80,96478,508* Amounts recorded by our Variable Interest Entities that have been excluded from net income attributable to Cephalon, Inc.Notes to Reconciliation of GAAP Net Income to Adjusted Net Income(1) To exclude the on-going amortization of acquired intangible assets ($30.3M in 2010; $26.9M in 2009), accelerated depreciation related to restructuring ($0.2M in 2010; $5.0M in 2009) and the reserve for modafinil purchase commitments in excess of requirements ($3.0M in 2009).
(2) In 2010, to exclude costs associated with our collaboration with Ambit Biosciences Corporation. In 2009, to exclude a
'/>"/>
| SOURCE Cephalon, Inc. Copyright©2010 PR Newswire. All rights reserved |